MedTrace Logo

Use of Direct Oral Anticoagulants in UK

NCT03119116 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31336

Last updated 2020-04-17

No results posted yet for this study

Summary

Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it. It is important to prescribe the correct dose of blood thinners to the right patients to ensure the treatment works however avoiding complications. In the recent years, new blood thinners have been available; they require less laboratory tests and fewer visits to a doctor compared to older therapies. This study will look at how the general practitioners in the UK prescribe blood thinners according to the instructions given by the product manufacturer. We will use primary care data that is routinely collected by the general practitioners about their patients but without any possibility to identify individual patients. The results will help us to understand the magnitude of deviation from instructions in order to ensure that the patients benefit from the treatment.

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD

DRUG

Dabigatran

Oral direct thrombin inhibitors, 75mg and 150mg capsules BID

DRUG

Apixaban

Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2017-10-16
Completion
2019-04-16

Countries

  • United Kingdom

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03119116 on ClinicalTrials.gov